Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
TOP1 x Top II | 1 |
Target- |
Mechanism Immunomodulators |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TOP1 inhibitors [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CCK receptor antagonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Jan 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2023 |
Sponsor / Collaborator |
Start Date15 Jun 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
DM-C | Inflammation More | Preclinical |
BMS-247615 ( TOP1 x Top II ) | Glioblastoma More | Preclinical |
TS-941 ( CCK receptor ) | Pancreatic Diseases More | Pending |